Seven years ago to the day, a new vehicle for gold launched straight into stardom and became the dominant means by which investors have gained exposure to the best-performing asset class of the last decade: gold.
The SPDR Gold Trust
With 41.46 million ounces (1,289.46 tonnes) in reported holdings, the GLD lays claim to more gold bullion than the combined (reported) sovereign holdings of India, Saudi Arabia, and the United Kingdom combined! The holdings equate to nearly one-half of all the gold mined in the world during 2010.The fund has further to climb, however, before matching the 140 million ounces of reserves held by the world's largest gold miner: Barrick Gold
Altering the landscape for gold investment
Although several exchange-traded bullion proxies were available prior to the launch of the GLD, no other vehicle has come close to capturing the attention -- nor the market share -- that the SPDR Gold Trust has commanded over recent years. The reported holdings of the iShares Gold Trust
Before these sorts of bullion proxies hit the stage, gold investors typically took possession of physical bullion and held onto the metal for the very long term. Between transportation and storage costs, the asset did not lend itself well to the whims of short-term traders, with futures markets offering essentially the sole exception. With the advent of the GLD and similar vehicles, short-term speculators and institutional investors alike now have a compelling niche at their disposal that lies somewhere in the void between actual physical possession and leveraged exposure to futures.
As the vehicle increases in scale, so does the imperative for gold investors to track the trust's data for emerging trends in investment demand for gold in the Western world. For example, John Paulson reportedly liquidated approximately one-third of his hedge fund's GLD holdings during the third quarter of 2011. I believe the sales likely stem from a rash of redemptions by clients in the wake of a couple of very rough quarters for the fund, and gold's strong trailing performance makes that holding an obvious target for strategic liquidation. Paulson reportedly sold 11.2 million shares of the GLD during the quarter, or the equivalent of about 1.1 million ounces of gold. A liquidation of that scale is certain to have an effect on gold price. After all, for all the attention it receives, gold remains a surprisingly minuscule market as compared with other asset classes. As gold continues to rise in price and popularity over the years to come -- a scenario that I consider a foregone conclusion -- the exceptional liquidity provided by the GLD will likely remain a conduit for substantial volatility.
Fortunately for gold investors, an incredible surge in central bank purchases of gold during the third quarter served to underpin the gold price in the face of a rallying U.S. dollar and the spate of forced hedge fund liquidations as bullish bets turned sour over the summer. Central banks added a phenomenal 148.4 tonnes of gold during the third quarter, representing a 123% sequential increase over the 66.5 tonnes purchased during the second quarter, and more than 6.5 times the prior-year mark of 22.6 tonnes. The identity of many of those buyers remains a mystery, though I suspect China may be overdue for another public restatement of its official gold holdings. In any event, those 4.77 million ounces in central bank purchases represent the strong bullish hand of willing buyers on the other end of those sudden liquidations by Paulson and others. With central bank gold purchases forecast to continue in earnest, the outlook for gold remains, well ... golden.
A golden record of performance
One would have to have dug pretty deep into a bag of tricks to outperform the GLD over the past seven years of a lost decade for stocks. Thank goodness for Apple
Over the seven years since the SPDR Gold Trust entered the fray, the trust has edged out even the rather epic performances logged by celebrated large-cap stocks Google and McDonald's
I find it interesting to note here, though, that a lesser-known and far-smaller bullion proxy has outperformed even the mighty GLD. I refer to Central Fund of Canada
But the greatest outperformers of all, I maintain, will be the miners of gold and silver. After a terrible year thus far in 2011, the mining equities are ludicrously undervalued and poised for substantial outperformance of bullion. I believe bullion exposure remains a core component of any well-structured strategy for precious-metals investment, but at this juncture I recommend an enhanced relative allocation to miners over bullion. I think Primero Mining
To mark the occasion of the SPDR Gold Trust's seven-year anniversary, take a moment to share with your fellow readers your strategy and/or selections for precious metal investment to profit from the remaining years of this powerful bull market. Whatever your thoughts on gold bullion or gold miners as an investment, Foolish minds want to know. Please find the comments section below.
Fool contributor Christopher Barker owns shares of Central Fund of Canada, AuRico Gold, and Primero Mining, but he holds no other position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Primero Mining, Google, and Apple. Motley Fool newsletter services have recommended buying shares of Apple, Google, McDonald's, and The Goldman Sachs Group. Motley Fool newsletter services have recommended creating a bull call spread position in Apple. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why the Apple Inc. iPhone X Isn't Doing as Well as Hoped in China
The answer might surprise you.
3 Signs You're Better Off Delaying Retirement
If you're coping with any of the issues below, then retiring now is probably a bad idea.
Better Buy: Gilead Sciences, Inc. vs. Pfizer Inc.
Which stock wins in a head-to-head match-up between the big biotech and the big pharma company?